PDS Biotechnology Corp Finance Lease, Liability, to be Paid, Year One
PDS Biotechnology Corp (PDSB) had Finance Lease, Liability, to be Paid, Year One of $40.11 thousand as of 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Finance Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths · last filed 2026-03-30
- 2025-12-31: Finance Lease, Liability, to be Paid, Year One $40.11K.
- 2025-09-30: Finance Lease, Liability, to be Paid, Year One $40.11K.
- 2025-06-30: Finance Lease, Liability, to be Paid, Year One $40.11K.
- 2025-03-31: Finance Lease, Liability, to be Paid, Year One $40.11K.
| Period end | Finance Lease, Liability, to be Paid, Year One |
|---|---|
| 2025-12-31 | $40.11K 10-K · filed 2026-03-30 |
| 2025-09-30 | $40.11K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $40.11K 10-Q · filed 2025-08-13 |
| 2025-03-31 | $40.11K 10-Q · filed 2025-05-14 |
| 2024-12-31 | $69.85K 10-K · filed 2025-03-27 |
| 2024-09-30 | $69.85K 10-Q · filed 2024-11-14 |
| 2024-06-30 | $69.85K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $69.85K 10-Q · filed 2024-05-15 |
| 2023-12-31 | $69.85K 10-K · filed 2024-03-28 |
| 2023-09-30 | $69.85K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $69.85K 10-Q · filed 2023-08-14 |
| 2023-03-31 | $69.85K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $74.10K 10-K · filed 2023-03-28 |
| 2022-09-30 | $44.36K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |